Oppenheimer raised the firm’s price target on Viking Therapeutics to $116 from $46 and keeps an Outperform rating on the shares. The positive topline results from the Phase 2 VENTURE trial of VK2735 are “the best-case scenario,” says the analyst, who believes Viking has multiple options to explore additional dosing regimens and further optimize the safety/efficacy profile and improve the patient experience given the “promising results.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics Issues Regulation FD Disclosure Notice
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics rumor highlighted again by Betaville blog
- Viking Therapeutics price target raised to $35 from $30 at Stifel
- Viking Therapeutics price target raised to $38 from $32 at Truist